Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease

Código QR

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease

Lin Chen,1,* Xiujuan Zhang,2,* Li Zhang,3 Dongmei Zheng2 1Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People’s Republic of China; 2Department of Endocrinology, Shandong Provincial Hospital Affili...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chen L, Zhang X, Zhang L, Zheng D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	dipeptidyl peptidase 4 inhibitor non-alcoholic fatty liver disease inflammation insulin resistance Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/0a588079ca504ff588952d8b77168fb7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Saxagliptin for type 2 diabetes
por: Chacra
Publicado: (2010)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

The Effect of Bioactive Polyphenols from <i>Anacardium occidentale</i> Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities
por: Nur Imanina Abdullah Thaidi, et al.
Publicado: (2020)

Molecular Dynamics Simulations Study of the Interactions between Human Dipeptidyl-Peptidase III and Two Substrates
por: Shitao Zhang, et al.
Publicado: (2021)

Gliptins vs. Milk-derived Dipeptidyl-Peptidase IV Inhibiting Biopeptides: Physicochemical Characterization and Pharmacokinetic Profiling
por: Jorge Andrés Barrero, et al.
Publicado: (2021)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar CS, et al.
Publicado: (2013)

Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies
por: Aleksandr E. Nosov, et al.
Publicado: (2021)

Dipeptidyl peptidase-IV inhibitory action of Calebin A: An in silico and in vitro analysis
por: Nehru Sai Suresh Chalichem, et al.
Publicado: (2021)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
por: Hiroshi Kasamatsu, et al.
Publicado: (2021)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma SK, et al.
Publicado: (2016)

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
por: Gharaibeh NE, et al.
Publicado: (2019)

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
por: Pegah Golabi, et al.
Publicado: (2022)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Siyu Yu, et al.
Publicado: (2021)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
por: Sue Shea, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease and Hypothyroidism: Review of Clinical and Experimental Studies
por: Tetiana Ranhulova
Publicado: (2021)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)

Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar R, et al.
Publicado: (2018)

The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
por: Hao Xu, et al.
Publicado: (2021)

Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
por: Liang XY, et al.
Publicado: (2021)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
por: Cosenso-Martin LN, et al.
Publicado: (2020)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes
por: Tan Y, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease as a Risk for Colorectal Cancer Development and the Role of Screening Colonoscopy in Clinical Practice
por: Cosmas Rinaldi Adithya Lesmana, et al.
Publicado: (2019)

Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry
por: Alswat K, et al.
Publicado: (2021)

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Satoru Hagiwara, et al.
Publicado: (2021)

Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
por: Aleksandr I. Pavlov, et al.
Publicado: (2021)

Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians
por: Mahamid M, et al.
Publicado: (2018)

Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease
por: Szanto KB, et al.
Publicado: (2019)

Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease, South Iran: A Population-Based Study
por: Sepehrimanesh M, et al.
Publicado: (2020)

Salidroside-Mitigated Inflammatory Injury of Hepatocytes with Non-Alcoholic Fatty Liver Disease via Inhibition TRPM2 Ion Channel Activation
por: Feng Q, et al.
Publicado: (2019)

The new drug saxagliptin is now registrated in Russia
por: Editorial team Diabetes Mellitus
Publicado: (2010)

Current concepts of the pathogenesis of non-alcoholic fatty liver disease
por: Evgenia Pavlovna Kosobyan, et al.
Publicado: (2010)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh CJ, et al.
Publicado: (2014)

A Non-Invasive Prediction Model for Non-Alcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Based on the Population of Northern Urumqi, China
por: Xue M, et al.
Publicado: (2021)